Aclaris Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Aclaris Therapeutics has a total shareholder equity of $130.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $182.4M and $52.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$127.72m |
| Equity | US$130.15m |
| Total liabilities | US$52.24m |
| Total assets | US$182.39m |
Recent financial health updates
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Recent updates
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28Financial Position Analysis
Short Term Liabilities: ACRS's short term assets ($132.3M) exceed its short term liabilities ($18.8M).
Long Term Liabilities: ACRS's short term assets ($132.3M) exceed its long term liabilities ($33.4M).
Debt to Equity History and Analysis
Debt Level: ACRS is debt free.
Reducing Debt: ACRS has no debt compared to 5 years ago when its debt to equity ratio was 35.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACRS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ACRS has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 8.7% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 21:05 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |
| Gavin Clark-Gartner | Evercore ISI |